Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.57 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.57 |
| ▸ | TGM2 | P21980 | 1/20 | 0.52 |
| ▸ | MGLL | Q99685 | 2/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10756101 | 0.96 | DPP8 (0.59) | DPP8DPP9TGM2MGLLRAB9A | |
| SCHEMBL6397529 | 0.92 | DPP8 (0.54) | DPP8DPP9TGM2MGLLRAB9A | |
| SCHEMBL10500161 | 0.89 | DPP8 (0.58) | DPP8DPP9TGM2MGLLRAB9A | |
| SCHEMBL6418689 | 0.88 | DPP8 (0.58) | DPP8DPP9TGM2MGLLRAB9A | |
| SCHEMBL10825541 | 0.86 | DPP8 (0.57) | DPP8DPP9TGM2MGLLRAB9A | |
| SCHEMBL6624294 | 0.86 | DPP8 (0.57) | DPP8DPP9TGM2MGLLRAB9A | |
| SCHEMBL11391394 | 0.86 | DPP8 (0.57) | DPP8DPP9TGM2MGLLRAB9A | |
| SCHEMBL13647947 | 0.86 | MGLL (0.67) | DPP8DPP9TGM2MGLLRAB9A | |
| SCHEMBL6942547 | 0.85 | HTT (0.68) | DPP8DPP9TGM2MGLLRAB9A | |
| SCHEMBL11099186 | 0.85 | DPP8 (0.56) | DPP8DPP9TGM2MGLLRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0042026-A1 | 3,4-Disubstituted azetidin-2-on compounds and process for their preparation | CIBA-GEIGY AG (CH) | 1981-12-23 | — | — | EP | claimed |
| US-20050004092-A1 | Penem derivatives and antimicrobial agent containing the same | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2005-01-06 | — | — | US | disclosed |
| EP-0757051-B1 | PENEM DERIVATIVES AND ANTIMICROBIAL AGENT CONTAINING THE SAME | DAIICHI SUNTORY PHARMA CO LTD (JP) | 2003-10-29 | — | — | EP | disclosed |
| US-6051569-A | 1'S, 5R, 6R-carbapenem derivatives and antimicrobial agents comprising the same | SUNTORY LIMITED (JP) | 2000-04-18 | — | — | US | disclosed |
| EP-0826687-A1 | Carbapenem derivatives and antimicrobial agents comprising the same | SUNTORY LIMITED (JP) | 1998-03-04 | — | — | EP | disclosed |
| EP-0774465-A1 | Penem derivatives and antimicrobial agents containing the same | SUNTORY LIMITED (JP) | 1997-05-21 | — | — | EP | disclosed |
| EP-0757051-A1 | PENEM DERIVATIVES AND ANTIMICROBIAL AGENT CONTAINING THE SAME | SUNTORY LIMITED (JP) | 1997-02-05 | — | — | EP | disclosed |
| EP-0001627-B1 | 3-SUBSTITUTED-6-(1'HYDROXETHYL)-7-OXO-1-AZABICYCLO(3.2.0.)-HEPT-2-ENE-2-CARBOXYLIC ACID, ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING IT | MERCK & CO. INC. (US) | 1984-04-04 | — | — | EP | disclosed |
| EP-0074599-A1 | 5,6-cis-Carbapenem derivatives, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1983-03-23 | — | — | EP | disclosed |
| US-4347367-A | ANTIBIOTICS | MERCK & CO., INC. (US) | 1982-08-31 | — | — | US | disclosed |
| US-4218463-A | ANTIBIOTICS | MERCK & CO., INC. (US) | 1980-08-19 | — | — | US | disclosed |
| EP-0001627-A1 | 3-Substituted-6-(1'hydroxethyl)-7-oxo-1-azabicyclo(3.2.0.)-hept-2-ene-2-carboxylic acid, its preparation and pharmaceutical compositions containing it | MERCK & CO. INC. (US) | 1979-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004092-A1 | Penem derivatives and antimicrobial agent containing the same | MRPL21, MRPS2, MRPS28 | DPP8 1319/4885DPP9 2823/4885TGM2 725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.